BRIEF REPORT

Interferon-α Induction and Detection of Anti-Ro, Anti-La, Anti-Sm, and Anti-RNP Autoantibodies by Autoantigen Microarray Analysis in Juvenile Dermatomyositis

Imelda Balboni,1 Timothy B. Niewold,2 Gabrielle Morgan,3 Cindy Limb,1 Maija-Leena Eloranta,4 Lars Rönnblom,4 Paul J. Utz,4 and Lauren M. Pachman5

Objective. To evaluate serum interferon-α (IFNα) activity in the context of autoantibody profiles in patients with juvenile dermatomyositis (JDM).

Methods. Sera from 36 patients with JDM were analyzed. Autoantibody profiles were determined by probing microarrays, which were fabricated with ~80 distinct autoantigens, with serum and a Cy3-conjugated secondary antibody. Arrays were scanned and analyzed to determine antigen reactivity. Serum IFNα activity was measured using a functional reporter cell assay. Sera were assayed alone or in combination with cellular material released from necrotic U937 cells to stimulate peripheral blood mononuclear cells from healthy donors in vitro, and IFNα production in culture was measured by a dissociation-enhanced lanthanide fluorimunoassay (DELFIA).

Results. Reactivity against at least 1 of 41 autoantigens on the microarray, including Ro 52, Ro 60, La, Sm, and RNP, was observed in 75% of the serum samples from patients with JDM. IFNα activity was detected in 7 samples by reporter cell assay. The reporter cell assay showed a significant association of reactivity against Ro, La, Sm, and proliferating cell nuclear antigen with serum IFNα activity (P = 0.005). Significance Analysis of Microarrays (SAM) identified increased reactivity against Sm, RNP, Ro 52, U1-C, and Mi-2 in these sera. Sixteen samples induced IFNα production as measured by DELFIA, and there was a significant association of reactivity against Ro, La, Sm, and RNP with the induction of IFNα by serum and necrotic cell material (P = 0.034). SAM identified increased reactivity against Ro 60 in these sera.

Conclusion. These data support the hypothesis that nucleic acid–associated autoantibodies, including the Ro/La and Sm/RNP complexes, may stimulate the production of active IFNα in children with JDM.

Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of childhood, is a systemic vasculopathy with a mean age at onset of 6.7 years and a female predominance of 2.3:1 (1). Diagnosis is based on the Bohan and Peter criteria (2,3). The pathophysiology of JDM is likely autoimmune, and both genetic and environmental factors have been implicated. The majority of patients with JDM are positive for antinuclear antibodies...
Type I interferons (IFNs) appear to play a role in JDM. Transcript profiling of muscle tissue from untreated patients with JDM demonstrated increased expression of several type I IFN–inducible genes (5). Transcript profiling has also shown up-regulation of type I IFN–inducible genes in peripheral blood mononuclear cells (PBMCs) from patients with JDM (6). Comparison of transcript profiles of PBMCs from healthy children, patients with JDM, and patients with pediatric systemic lupus erythematosus (SLE) demonstrated up-regulation of type I IFN–regulated transcripts in 50% of the patients with active JDM, and this type I IFN signature overlapped with, but was distinct from, the type I IFN signature identified in patients with pediatric SLE (6). In addition, IFNα activity in sera from untreated patients with JDM was increased compared to that in sera from age-matched controls (7). Furthermore, sera from adult myositis patients with Jo-1 or Ro 52/Ro 60 autoantibodies induced IFNα production in healthy donor PBMCs (8). Those studies suggest that both type I IFN proteins and IFN-inducible genes are up-regulated in myositis and may be critical in disease pathogenesis.

Autoantigen microarrays allow the comprehensive evaluation of autoantibodies directed against dozens of autoantigens using microliter quantities of serum (9). Antibody binding to autoantigens on microarrays has been shown to be 4–8 times more sensitive than enzyme-linked immunosorbent assays (ELISAs), with specific antibody binding demonstrated over a 1,000-fold range (10). The purpose of this pilot study was to characterize the autoantibodies present in the sera of patients with JDM using autoantigen microarrays and to determine whether serologic IFNα activity correlates with the presence of specific autoantibodies.

### PATIENTS AND METHODS

**Patients.** Thirty-six patients (28 females and 8 males with a median age of 10.5 years) with definite/probable JDM (based on the Bohan and Peter criteria) and 10 controls (with a median age of 11 years) were included in the study. Patient demographics and clinical characteristics at the time of sample collection are shown in Supplementary Table 1 (available on the Arthritis & Rheumatism web site at http://onlinelibrary.wiley.com/doi/10.1002/art.38038/abstract). Skin and muscle disease activity were evaluated using the validated Disease Activity Score (DAS) (11). The Institutional Review Board at the Ann and Robert H. Lurie Children’s Hospital of Chicago Research Center approved the study (IRB #2002-11762), and age-appropriate informed consent was obtained. Sera from 10 of the patients with JDM (28%) were positive for myositis-specific autoantibodies (MSAs) or myositis-associated autoantibodies (MAAs), including anti-Ro, anti–Mi-2, anti–U1 RNP, anti–U2 RNP, anti–Scl-70, anti–PM-Scl, and anti–signal recognition particle (12).

**Autoantigen microarrays.** Autoantigen microarrays were generated by spotting distinct autoantigens in replicates using a VersArray ChipWriter Pro microarrayer (Bio-Rad) with a customized printhead and Silicon Microarray Spotting Pins (ParallelSynthesis Technologies) as previously described (10). A complete list of these autoantigens is provided in Supplementary Table 2 (available on the Arthritis & Rheumatism web site at http://onlinelibrary.wiley.com/doi/10.1002/art.38038/abstract).
expression of 3 IFN polymerase chain reaction was used to measure the relative JDM, lysed, and RNA was isolated. Real-time quantitative cell line) were cultured for 6 hours with sera from patients with JDM, controls, and RNA was isolated. Relative expression data from these transcripts were normalized using the mean and SD of healthy donor sera (n = 10) that were run in the same assay, and data are presented as an IFN activity score. The serum-induced reporter cell activity can be blocked with anti-IFNα monoclonal antibodies, and no significant functional inhibitors have been detected (14).

**IFNα inducers and culture of PBMCs.** PBMCs from healthy donors were cultured in 96-well plates with 4 different concentrations of patient or healthy control sera, ranging from 0.001% to 1%, alone or in combination with 10% necrotic material from U937 cells. Each serum sample was used to stimulate PBMCs from 2 healthy donors. Ultraviolet light–inactivated herpes simplex virus type 1 and serum from an SLE patient were used as positive controls. After 20 hours, IFNα levels in the cell culture supernatants were measured by a dissociation-enhanced lanthanide fluoroimmunoassay (15). The cutoff level, based on the level induced by the healthy control sera, was set at 21 units/ml.

**Statistical analysis.** For the autoantigen microarrays, quantitative analysis of the fluorescence intensity of individual features was performed using GenePix Pro software version 6.1 (Molecular Devices). The fluorescence intensity of each feature was determined based on the median pixel intensity within the circumscribed antigen feature minus the background. The median fluorescence intensity minus background (MFI-B) was calculated for each antigen. For each individual sample from patients with JDM, reactivity against an antigen was considered to be significant if the MFI-B for the antigen was more than 3 SD above the mean MFI-B for that antigen in the 10 control samples.

**RESULTS**

Evaluation of the MFI-B for each patient with JDM compared to the mean MFI-B of controls revealed that 27 patients with JDM (75%) had reactivity against at least 1 of 41 antigens on the microarray (Table 1). The number of patients with reactivity against each of these antigens ranged from 1 (3%) to 6 (17%). The majority of sera demonstrated reactivity against one or two antigens while some sera had a broader spectrum of reactivity (Table 1).

Two MSAs, anti–Mi-2 and anti–PL-12, and several MAAs, including anti-La, anti–Ro 52, anti–Ro 60, anti–U1 RNPs, and anti-Ku antibodies, were identified in this JDM cohort (Table 1). Several of the other reactivities observed were against autoantigens associated with SLE, including histones, Sm, and proliferating...
Given that PBMCs from a subset of patients with JDM have an IFN signature, we used a reporter cell assay to further characterize sera from this JDM cohort for the ability to induce IFNα activity (14). Of the JDM patient sera assayed, most did not induce up-regulation of the IFNα-regulated genes, 2 induced high IFNα activity (++++), and 5 induced low activity (+), as shown in Figure 1A and Table 2. Typical values for normal pediatric and adult sera are between 0 and 2.

There was an association between the induction of serum IFNα activity in the reporter cell assay and positivity for anti-Ro, anti-La, anti-Sm, or anti-PCNA specificities. Serum IFNα activity was induced by sera...
from 6 of the 13 patients who were positive for 1 of these autoantibodies versus only 1 of the 23 patients who were negative for these antibodies ($P = 0.005$). Similarly, there was an association between serum IFNα activity and autoantibody positivity in patients with reactivity against any DNA-associated antigen, with serum from 6 of the 16 patients who were positive for 1 of these antibodies inducing serum IFNα activity, as compared to serum from only 1 of the 21 patients who were negative for these antibodies ($P = 0.039$). The 2 serum samples with high IFNα activity also had strong reactivity against components of the Sm/RNP complex, and all of the samples with IFNα activity in the reporter cell assay demonstrated reactivity against at least 1 nucleic acid–associated autoantigen (Table 2). SAM identified increased reactivity against several of these antigens, including Ro 52, Sm/RNP, U1-C, and Mi-2, in sera positive for the receptor cell assay (data not shown).

Previous studies have demonstrated that SLE sera combined with apoptotic U937 cells induce healthy donor PBMCs to produce IFNα in vitro (15). We evaluated sera from patients in this JDM cohort for the ability to induce IFNα production using this assay. Sixteen serum samples induced IFNα production and thus had the capacity to generate interferogenic immune complexes, as seen in Figure 1B. There was an association between IFNα production and reactivity against Ro, La, Sm, and RNP antigens ($P = 0.034$). In addition, several of the 16 positive samples demonstrated reactivity against other nucleic acid–associated antigens, including Ro 52, La, CENP-B, Mi-2, and components of the Sm/RNP complex (Table 2). SAM identified increased reactivity against Ro 60 in sera positive for this assay (data not shown).

**DISCUSSION**

This is the first study to evaluate autoantibody reactivity against a large number of antigens in JDM using antigen microarrays. Using the stringent cutoff of MFI-B greater than 3 SD above the mean MFI-B in the control group to determine significant reactivity, we demonstrated an unexpectedly broad spectrum of autoantibodies in this JDM cohort. These included MSAs and MAAs, autoantibodies classically associated with SLE and other autoimmune diseases, as well as other autoantibodies not previously described in JDM. The frequency of MSAs in our cohort was similar to that found in previous studies, while our cohort had an increased frequency of certain MAAs, including anti-Ro, anti-La, and anti–U1 RNP (17). This likely reflects the increased sensitivity of the antigen microarrays compared to standard immunoassays such as ELISA (10).

Despite the presence of autoantibody reactivity in the majority of sera from patients with JDM, it is not surprising that SAM did not identify reactivity that distinguished the JDM cohort as a whole from the control subjects or that distinguished between ANA-positive and ANA-negative subgroups of JDM patients, due to the small percentage of patients with reactivity against any given antigen (3–17%) (Table 1). Interestingly, many of the autoantibodies identified were directed against nuclear antigens, and these reactivities could be the source of the positive ANAs without known specificity. However, these reactivities do not account for all 72% of the ANA positivity in this cohort, suggesting that additional nuclear antigens not present on our microarray are likely present in some patients with JDM. This is a known limitation of antigen microarray technology, which is a biased assay that only detects reactivity to the predetermined antigens printed on the microarray. In particular, the microarrays manufactured for this study did not include the p155/140 antigen that was recently identified in >20% of patients with JDM (18).

This study demonstrated that sera from some patients with JDM had the ability to induce IFNα activity or production in two in vitro assays (Figure 1). In fact, there was a correlation between the presence of antibodies against RNA-containing autoantigens and both serum IFNα activity and the capacity to generate interferogenic immune complexes. In particular, SAM identified Ro 52 and Ro 60 reactivity as being significantly associated with the ability of the sera to induce IFNα production in vitro, and Ro 52, Sm/RNP, and U1-C reactivity was associated with IFNα activity in the reporter cell assay. Consequently, antibodies to RNA-binding proteins seem to be critical elements in the process that leads to increased IFNα production in a subset of patients with JDM. However, there are some limitations of this study. For example, given that the family history of SLE in children with JDM is associated with increased IFNα activity (19), it is possible that unrecognized family linkages might be the source of the low levels of La, Ro 52, and Ro 60. Still, SAM did not identify an increased reactivity to any antigens when comparing JDM patients with a family history of SLE to those without a family history of SLE (data not shown).

In conclusion, a broad spectrum of autoantibodies is produced in patients with JDM, and sera with antibodies directed against RNA-containing autoantigens induce IFNα activity or production in vitro. We
hypothesize that RNA-containing autoantigens, including Ro, La, Sm, and RNP, play a critical role in the activation of the type I IFN system in JDM and are an essential component of the autoimmune disease process. Further studies are needed to elucidate the mechanisms by which this activation contributes to the pathogenesis of JDM.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Balboni had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Balboni, Pachman.

Acquisition of data. Balboni, Niewold, Morgan, Limb, Eloranta, Rönnblom, Pachman.

Analysis and interpretation of data. Balboni, Niewold, Limb, Eloranta, Utz, Pachman.

REFERENCES